Literature DB >> 10767724

Nicotinamide prevents the development of diabetes in the cyclophosphamide-induced NOD mouse model by reducing beta-cell apoptosis.

B A O'Brien1, B V Harmon, D P Cameron, D J Allan.   

Abstract

The development of diabetes in non-obese diabetic (NOD) mice, which normally takes between 3 and 7 months, can be accelerated by cyclophosphamide (CY) injections, with rapid progression to diabetes within only 2-3 weeks. This insulin-dependent diabetes mellitus (IDDM) can be prevented or delayed in CY-treated NOD mice by nicotinamide (NA). The present study was undertaken to determine the mode of cell death responsible for the development of IDDM in CY-treated male NOD mice and to investigate the effect of NA on beta-cell death. Apoptotic beta cells were present within the islets of Langerhans in haematoxylin and eosin-stained sections of the pancreata harvested from 3- and 12-week-old male NOD mice, from 8 h until 14 days after a single intraperitoneal injection of CY (150 mg/kg body weight). The maximum amount of beta-cell apoptosis in 3-week-old animals occurred 1-2 days after CY treatment (20 apoptotic cells per 100 islets), after which time levels of apoptosis declined steadily throughout the 14-day period studied. The incidence of beta-cell apoptosis in 12-week-old male NOD mice occurred in two peaks; the first was recorded 8-24 h after CY treatment (30 apoptotic cells/100 islets), while the second, at 7 days (36 apoptotic cells per 100 islets), coincided with increased insulitis. Administration of NA 15 min before CY treatment, and thereafter daily, substantially reduced the amount of apoptosis and effectively eliminated (4 apoptotic cells per 100 islets) the second wave of beta-cell apoptosis seen at day 7 in 12-week-old animals given CY alone. These results show that apoptosis is the mode of beta-cell death responsible for the development of CY-induced IDDM and that prevention of IDDM by NA is associated with a reduction in beta-cell apoptosis. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10767724     DOI: 10.1002/(SICI)1096-9896(200005)191:1<86::AID-PATH573>3.0.CO;2-0

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  Transgenic expression of Hsc70 in pancreatic islets enhances autoimmune diabetes in response to beta cell damage.

Authors:  Masih-ul Alam; Julie A Harken; Anna-Maria Knorn; Alisha R Elford; Kip Wigmore; Pamela S Ohashi; Douglas G Millar
Journal:  J Immunol       Date:  2009-10-07       Impact factor: 5.422

2.  The sirtuin inhibitor nicotinamide enhances neuronal cell survival during acute anoxic injury through AKT, BAD, PARP, and mitochondrial associated "anti-apoptotic" pathways.

Authors:  Zhao-Zhong Chong; Shi-Hua Lin; Faqi Li; Kenneth Maiese
Journal:  Curr Neurovasc Res       Date:  2005-10       Impact factor: 1.990

3.  Effects of N1-methylnicotinamide on oxidative and glycooxidative stress markers in rats with streptozotocin-induced diabetes mellitus.

Authors:  Zuzana Országhová; Ol'ga Uličná; Anna Liptáková; Ingrid Zitňanová; Jana Muchová; Cezary Watala; Zdeňka Duračková
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

4.  Increased susceptibility to streptozotocin-induced beta-cell apoptosis and delayed autoimmune diabetes in alkylpurine-DNA-N-glycosylase-deficient mice.

Authors:  J W Cardinal; G P Margison; K J Mynett; A P Yates; D P Cameron; R H Elder
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 5.  Immunotherapy of type 1 diabetes: where are we and where should we be going?

Authors:  Xunrong Luo; Kevan C Herold; Stephen D Miller
Journal:  Immunity       Date:  2010-04-23       Impact factor: 31.745

6.  Dietary zinc reduction, pyruvate supplementation, or zinc transporter 5 knockout attenuates β-cell death in nonobese diabetic mice, islets, and insulinoma cells.

Authors:  Christian T Sheline; Chunxiao Shi; Toshihiro Takata; Julia Zhu; Wenlan Zhang; P Joshua Sheline; Ai-Li Cai; Li Li
Journal:  J Nutr       Date:  2012-10-24       Impact factor: 4.798

7.  Involvement of SIRT1 in Zn2+, Streptozotocin, Non-Obese Diabetic, and Cytokine-Mediated Toxicities of β-cells.

Authors:  Christian T Sheline
Journal:  J Diabetes Metab       Date:  2012-05-31

Review 8.  Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide.

Authors:  Seon Beom Song; Jin Sung Park; Gu June Chung; In Hye Lee; Eun Seong Hwang
Journal:  Metabolomics       Date:  2019-10-05       Impact factor: 4.290

9.  Protective effects of a nicotinamide derivative, isonicotinamide, against streptozotocin-induced β-cell damage and diabetes in mice.

Authors:  Makiko Fukaya; Yoshiaki Tamura; Yuko Chiba; Toshihiro Tanioka; Ji Mao; Yoko Inoue; Marina Yamada; Christian Waeber; Yukari Ido-Kitamura; Tadahiro Kitamura; Masao Kaneki
Journal:  Biochem Biophys Res Commun       Date:  2013-11-15       Impact factor: 3.575

10.  TSG-6 produced by hMSCs delays the onset of autoimmune diabetes by suppressing Th1 development and enhancing tolerogenicity.

Authors:  Daniel J Kota; Lindsey L Wiggins; Nara Yoon; Ryang Hwa Lee
Journal:  Diabetes       Date:  2013-01-24       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.